Thalassemia Treatment Market, By Type (Alpha-Thalassemia and Beta-Thalassemia), By Treatment (Blood Transfusions, Iron Chelation Therapy, Folic Acid Supplements, Gene Therapy and Bone Marrow Transplant), By End-User (Hospitals & Clinics, Diagnostic Laboratories and Others), and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Trends, Analysis, and Forecast till 2030

Report Code: PMI468021 | Publish Date: August 2023 | No. of Pages: 168

Global Thalassemia Treatment Market Overview

Thalassemia is an inherited blood disorder characterized by decreased hemoglobin production. Symptoms depend on the type and vary from mild to severe. Anemia can result in tiredness and pale skin. There may also be bone problems, enlarged spleen, yellowish skin and dark urine. Thalassemia is inherited genetic disorders. There are two main types, alpha thalassemia and beta thalassemia. The severity of alpha and beta thalassemia depends on the absence four genes for alpha globin or two genes for beta globin. Diagnosis is typically by blood tests including a complete blood count, special hemoglobin test, and genetic test. Diagnosis may occur before birth through prenatal testing. As of 2015, thalassemia occurred in 280 million people, with about 439,000 having severe disease. The Thalassemia Treatment Market accounted for US$ 2.3 billion in 2020 and is estimated to be US$ 14.7 billion by 2030 and is anticipated to register a CAGR of 10.40%.

Impact of Covid-19 pandemic on market

Number of patients suffering from thalassemia is rising day by day. Disruption in supply chain and complete lockdown in various countries resulted in shortage of products which will hamper the market of thalassemia treatment. This report will quantify the impact of this pandemic on the market.

Global Thalassemia Treatment Market Dynamics

Chelation Therapy might boost the market

High content of iron is the main cause of sickness for thalassemia patients. Even non-transfused patients develop iron overload secondary to boost intestinal absorption of dietary iron and chelation therapy is the only treatment to remove excess iron which boost the market.

Increasing patients of Thalassemia

Increasing patients of thalassemia and increasing awareness among the people through government also drives the market of Thalassemia treatment.

Access Crucial Insights at a Fraction of the Cost | Request Your Discount

Global Thalassemia Treatment Market Segmentation

Source: Prophecy Market Insights

 

The Global Thalassemia Treatment Market is segmented based on type, treatment, end-user and region.

On the basis of type, the Global Thalassemia Treatment Market is segmented into Alpha-thalassemia and Beta-thalassemia. Based on Treatment, the target market is segmented into Blood Transfusions, Iron Chelation Therapy, Folic Acid Supplements, Gene Therapy and Bone Marrow Transplant. On the basis of end-user, the target market is segmented into Hospitals & Clinics, Diagnostic Laboratories and Others.

Regional Insights:

On region the Global Thalassemia Treatment Market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is dominating with highest share revenue due to increasing thalassemia patients, highly advanced healthcare infrastructure, highly aware population and favorable government initiatives. Thalassemia is becoming more prevalent in the U.S. due to immigration of people from affected regions. For instance, according to the National Institute of Health, the overall prevalence of Thalassemia is around 5.4% in U.S.

Reduce costs by up to 30% with a custom report tailored to your specific needs | Request Customized Report

Attribute

Details

Base year for estimation

2020

Forecast period

2020 – 2030

Market representation

Revenue in USD Million & CAGR from 2020 – 2030

Market Segmentation

By Type- Alpha-thalassemia and Beta-thalassemia

By Treatment– Blood Transfusions, Iron Chelation Therapy, Folic Acid Supplements, Gene Therapy and Bone Marrow Transplant

By End-User– Hospitals & Clinics, Diagnostic Laboratories and Others.

Regional scope

North America - U.S., Canada

Europe - UK, Germany, Spain, France, Italy, Russia, Rest of Europe

Asia Pacific - Japan, India, China, South Korea, Australia, Rest of Asia-Pacific

Latin America - Brazil, Mexico, Argentina, Rest of Latin America

Middle East & Africa - South Africa, Saudi Arabia, UAE, Rest of Middle East & Africa

Report coverage

Revenue forecast, company share, competitive landscape, growth factors, and trends

Segments Covered in the Report:

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2019 to 2030. For the purpose of this study, has segmented the Global Thalassemia Treatment Market report based on type, treatment, end-user and region.

Global Thalassemia Treatment Market, By Region:

      • North America
          • U.S.
          • Canada
      • Europe
          • Germany
          • UK
          • France
          • Russia
          • Italy
          • Rest of Europe
      • Asia Pacific
          • China
          • India
          • Japan
          • South Korea
          • Rest of Asia Pacific
      • Latin America
          • Brazil
          • Mexico
          • Rest of Latin America
      • Middle East & Africa
          • GCC
          • Israel
          • South Africa
          • Rest of Middle East & Africa

Global Thalassemia Treatment Market Key Players

The key players operating in the Global Thalassemia Treatment Market include Novartis AG (Switzerland), Bluebird Bio, Inc. (US), Kiadis Pharma (Netherlands), CELGENE CORPORATION (US), Sangamo Therapeutics (US), Acceleron Pharma, Inc. (US), Gamida Cell (Israel).

Global Thalassemia Treatment Market Company Profile

  • Novartis AG (Switzerland)
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • Bluebird Bio, Inc. (US)
  • Kiadis Pharma (Netherlands)
  • CELGENE CORPORATION (US)
  • Sangamo Therapeutics (US)
  • Acceleron Pharma, Inc. (US)
  • Gamida Cell (Israel)

 “*” marked represents similar segmentation in other categories in the respective section

Global Thalassemia Treatment Market Table of Contents

  1. Research Objective and Assumption
    • Preface
    • Research Objectives
    • Study Scope
    • Years Considered for the study
    • Assumptions
    • Abbreviations
  2. Research Methodology
    • Research data
    • Primary Data
      • Primary Interviews
      • Primary Breakdown
      • Key data from Primary Sources
      • Key Thickness Insights
    • Secondary Data
      • Major Secondary Sources
      • Secondary Sources
    • Market Estimation
    • Top-Down Approach
      • Approach for estimating Market Share by Top-Down Analysis (Supply Side)
    • Bottom-Up Approach
      • Approach for estimating market share by Bottom-up Analysis (Demand Side)
    • Market Breakdown and Data Triangulation
    • Research Assumptions
  3. Market Purview
    • Executive Summary
    • Key Findings—Global Outlook for Thalassemia Treatment Strategies
      • Key Questions this Study will Answer
      • Market Snippet, By Type
      • Market Snippet, By Treatment
      • Market Snippet, By End-User
      • Market Snippet, By Region
    • Opportunity Map Analysis
    • Executive Summary—3 Big Predictions
  4. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
      • Market Trends
    • DR Impact Analysis
    • PEST Analysis
    • Porter’s Five Forces Analysis
    • Opportunity Orbit
    • Market Investment Feasibility Index
    • Macroeconomic Factor Analysis
  5. Global Thalassemia Treatment Market, By Type, 2020 – 2030, (US$ Mn)
    • Overview
      • Market Value and Forecast (US$ Mn), and Share Analysis (%), 2020 – 2030
      • Y-o-Y Growth Analysis (%), 2020 – 2030
      • Segment Trends
    • Alpha-Thalassemia
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
    • Beta-Thalassemia
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
  6. Global Thalassemia Treatment Market, By Treatment, 2020 – 2030, (US$ Mn)
    • Overview
      • Market Value and Forecast (US$ Mn), and Share Analysis (%), 2020 – 2030
      • Y-o-Y Growth Analysis (%), 2020 – 2030
      • Segment Trends
    • Blood Transfusions
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
    • Iron Chelation Therapy
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
    • Folic Acid Supplements
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
    • Gene Therapy
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
    • Bone Marrow Transplants
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
  7. Global Thalassemia Treatment Market, By End-User, 2020 – 2030, (US$ Mn)
    • Overview
      • Market Value and Forecast (US$ Mn), and Share Analysis (%), 2020 – 2030
      • Y-o-Y Growth Analysis (%), 2020 – 2030
      • Segment Trends
    • Hospitals & Clinics
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
    • Diagnostic Laboratories
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
    • Others
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
  8. Global Thalassemia Treatment Market, By Region, 2020 – 2030, (US$ Mn)
    • Overview
      • Market Value and Forecast (US$ Mn), and Share Analysis (%), 2020 – 2030
      • Y-o-Y Growth Analysis (%), 2020 – 2030
      • Regional Trends
    • North America
      • Market Size and Forecast (US$ Mn), By Type, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Treatment, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By End-User, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Country, 2020 – 2030
        • U.S.
        • Canada
    • Europe
      • Market Size and Forecast (US$ Mn), By Type, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Treatment, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By End-User, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Country, 2020 – 2030
        • UK
        • France
        • Germany
        • Russia
        • Italy
        • Rest of Europe
    • Asia Pacific
      • Market Size and Forecast (US$ Mn), By Type, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Treatment, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By End-User, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Country, 2020 – 2030
        • India
        • Japan
        • South Korea
        • China
        • Rest of Asia Pacific
    • Latin America
      • Market Size and Forecast (US$ Mn), By Type, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Treatment, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By End-User, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Country, 2020 – 2030
        • Brazil
        • Mexico
        • Rest of Latin America
    • Middle East & Africa
      • Market Size and Forecast (US$ Mn), By Type, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Treatment, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By End-User, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Country, 2020 – 2030
        • GCC
        • Israel
        • South Africa
        • Rest of Middle East
  9. Competitive Landscape
    • Heat Map Analysis
    • Market Presence and Specificity Analysis
  10. Company Profiles
  • Novartis AG (Switzerland)
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • Bluebird Bio, Inc. (US)
  • Kiadis Pharma (Netherlands)
  • CELGENE CORPORATION (US)
  • Sangamo Therapeutics (US)
  • Acceleron Pharma, Inc. (US)
  • Gamida Cell (Israel)
  1. The Last Word
    • Future Impact
    • About Us
    • Contact

 

FAQs

The Global Thalassemia Treatment Market is segmented based on type, application, end-user and region.

Highly advanced healthcare infrastructure, highly aware population and favorable government initiatives are the major factor driving growth of the global market

North America is dominating with highest share revenue in Thalassemia treatment market.

The key players operating in the Global Thalassemia Treatment Market includes Novartis AG (Switzerland), Bluebird Bio, Inc. (US), Kiadis Pharma (Netherlands), CELGENE CORPORATION (US), Sangamo Therapeutics (US), Acceleron Pharma, Inc. (US), Gamida Cell (Israel).